A Phase I Study of R1507 in Children and Adolescents with Advanced Solid Tumors
[Protocol 07-142]
Full Title :
MULTIPLE ASCENDING DOSE (MAD) PHASE I STUDY OF THE IGF-1R ANTAGONIST R1507 ADMINISTERED AS AN INTRAVENOUS INFUSION IN CHILDREN AND ADOLESCENTS WITH ADVANCED SOLID TUMORS
Purpose :
R1507 is an investigational anticancer drug called a monoclonal antibody. R1507 targets the "insulin-like growth factor receptor 1 (IGF1R)," a specific protein on the surface of cancer cells that helps them to grow and divide. By blocking IGF1R, it is hoped that R1507 will stop the ability of cancer cells to divide and grow.
R1507 has been evaluated in laboratory studies and in clinical trials for adults with cancer. In this study, researchers want to find the highest dose of R1507 that can be given safely in children and adolescents with advanced solid tumors that do not respond to standard treatments or for which no standard treatments exist. R1507 is given intravenously (by vein).
Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
Patients must have an advanced solid tumor that does not respond to standard treatments or has returned following standard treatment, or for which no standard treatments exist.
Patients must be between the ages of 2 and 18 (inclusive).
Patients must have recovered from the major side effects of any prior therapies.
For more information and to inquire about eligibility for this study, please contact Dr. Tanya Trippett at 212-639-8267.
